Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Eliot N. Mostow MD, MPH Associate Editor

Sarah L. Chamlin MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · June 19, 2024

Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Article Citation

The Lancet

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Lancet 2024 Jun 08;403(10443)2504-2519, AB Kimball, GBE Jemec, CJ Sayed, JS Kirby, E Prens, JR Ingram, A Garg, AB Gottlieb, JC Szepietowski, FG Bechara, EJ Giamarellos-Bourboulis, H Fujita, R Rolleri, P Joshi, P Dokhe, E Muller, L Peterson, C Madden, M Bari, CC Zouboulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa

Additional Info

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Further Reading

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Efficacy of Treatment With Bimekizumab in Patients With Hidradenitis Suppurativa

Efficacy and Safety of Treatment With Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Relative Effect of a 0.8-mm Breslow Thickness on the Risk of Death Owing to Melanoma and Other Causes Among Patients With Thin Cutaneous Melanomas

Effectiveness of a Novel Treatment Regimen for Patients With Acne Vulgaris

Efficacy of a Novel Four-Step Skin Care Regimen in Improving Uneven Skin Tone

Outcomes of Treatment With CO2 Laser vs Surgical Deroofing in Patients With Hidradenitis Suppurativa Tunnels

Effectiveness of Treatment With Deucravacitinib in Patients With Plaque, Generalized Pustular, or Erythrodermic Psoriasis

Factors Associated With Maintenance of Clinical Response After Reducing the Dosing Frequency of Tralokinumab in Patients With Moderate to Severe Atopic Dermatitis

Recently Updated